Current evidence is inadequate to determine how DPP-4 inhibitors affect the risk of heart failure in patients with type 2 diabetes.

DPP-4 inhibitors use was used in 54% of treatment visits by the last quarter of 2014; ACEIs and ARBs were prescribed in the majority of treatment visits with peaks above 90%.